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Prevention of Healthcare-Associated Clostridium difficile Infection:
What Works?
Erik R. Dubberke, MD, MSPH
Prevention of Clostridium difficile infection has become extremely important because of increases in its incidence and severity. Unfortunately,
efforts at C. difficile infection prevention are hampered by lack of data to support optimal prevention methods, especially for endemic C.
difficile infection. Studies are needed to define the optimal prevention practices and to investigate novel prevention methods.
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Increases in the incidence and severity of Clostridium difficile
infection (CDI) have highlighted the need for proven meth-
ods to prevent CDI. Unfortunately, the current state of lit-
erature on CDI prevention is limited. There continue to be
many unanswered questions about how to best prevent CDI.
Most data come from single centers where multiple inter-
ventions are conducted in response to a CDI outbreak. These
bundled interventions in response to outbreaks can lead to
significant biases in the interpretation of the results and make
it difficult to know which interventions were truly effective.
In addition, some interventions that may prevent CDI in
settings where there is an outbreak appear to be less effica-
cious in settings where it is endemic. The recent changes in
CDI epidemiology indicate the need for more-effective meth-
ods to prevent CDI in both situations. Despite the many
unknowns regarding optimal methods for CDI prevention,
the increases in CDI incidence and severity require that all
acute care facilities must have a CDI prevention program.
There are several key components to a successful CDI pre-
vention program.1 There must be good communication be-
tween all healthcare workers who play a role in CDI preven-
tion and treatment, so that patients with CDI can be identified
rapidly for initiation of infection prevention measures and
CDI-specific treatment. Healthcare workers who play a role
in the prevention and treatment of CDI include infection
prevention specialists, hospital epidemiologists, physicians,
nurses, laboratory personnel, housekeeping staff, pharmacy
personnel, and hospital administrators.1 These individuals all
must know what their responsibilities are and must be held
accountable for their behavior, to ensure adherence to the
hospital’s CDI prevention policies and procedures. As the
group responsible for directing the CDI prevention program,
infection prevention and control specialists must be familiar
with the limitations in the CDI prevention literature. This is
particularly important if the healthcare facility is experiencing
a problem with CDI and it is necessary to determine which
“special approaches” for preventing CDI will most likely be
beneficial on the basis of local CDI epidemiology and health-
care worker adherence to CDI prevention measures.1
what works
The Compendium of Strategies to Prevent Healthcare-As-
sociated Infections in Acute Care Hospitals2 grades all rec-
ommended practices to prevent healthcare-associated infec-
tions on the basis of the strength of the recommendation and
the quality of evidence to support that recommendation (rec-
ommendations require a minimum strength of “B” to be
included). There are 16 recommended practices in the C.
difficile component of the Compendium.1 Twelve of the prac-
tices have a grade of “B-III,” or moderate strength of evidence
to support the recommendation and evidence from opinions
of respected authorities, clinical experience, or descriptive
studies. Two practices have a grade of “B-II,” or moderate
strength of evidence to support the recommendation and
evidence from nonrandomized trials, cohort or case-control
studies, multiple time series, or dramatic results of uncon-
trolled experiments. There are only 2 practices with a strength
of “A,” or good evidence to support the recommendation.
One has a grade of “A-II.” The other is the only recommended
practice to prevent CDI that has evidence from a randomized
trial and therefore has a grade of “A-I.”
The single recommended practice to prevent CDI that is
graded “A-I” is to wear gloves when caring for a patient with
CDI. A study conducted prior to the advent of universal and
standard precautions randomized 4 wards with similar base-
line rates of CDI to provide standard of care or to conduct
an educational intervention.3 The intervention consisted of
an educational campaign instructing nurses to wear gloves
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when handling body fluids, especially stool. Boxes of gloves
were placed at each patient’s bedside on the intervention
wards. There was a statistically significant decrease in CDI
incidence on the intervention wards, from 7.7 to 1.5 cases
per 1,000 patient-days ( ), and no significant changePp .015
in CDI incidence on the control wards (from 5.7 to 4.2 cases
per 1,000 patient-days). Point prevalence assessments of
asymptomatic C. difficile carriage were conducted before and
after the intervention. There was a statistically significant de-
crease in the proportion of patients colonized with C. difficile
on the intervention wards (from 27% to 9% of patients;
), but no significant difference on the control wardsPp .029
(from 17% to 10% of patients).
The recommended practice graded “A-II” is antimicrobial
stewardship. There are 2 primary approaches to using anti-
microbial stewardship to prevent CDI: restricting the use of
a single antimicrobial associated with a high risk of CDI, and
a more comprehensive approach focused on improving over-
all antimicrobial prescribing practices and reducing unnec-
essary antimicrobial exposures. Both approaches have been
successful during outbreaks, and improved antimicrobial pre-
scribing practices have been successful at decreasing the num-
ber of cases in settings where CDI is endemic, as well.4-6
cdi prevention and bundles
The current trend to apply recommended practices for health-
care-associated infection prevention is the “bundle ap-
proach.” The Keystone ICU Project demonstrated that an
easy-to-follow “bundle” of recommended practices can result
in dramatic decreases in the number of catheter-associated
bloodstream infections occurring in intensive care units.7 All
5 of the evidence-based practices selected for the bundle had
a “I-A” level of supporting evidence (the grading criteria used
in the 2002 Guidelines for the Prevention of Intravascular
Catheter-Related Infections and in the 2008 Strategies to Pre-
vent Clostridium difficile Infections in Acute Care Hospitals
are similar but not identical) and have low barriers to
implementation.7,8 In addition, the bundle used for the Key-
stone ICU Project had previously been demonstrated to be
successful in multiple healthcare settings.9,10 In contrast, there
are no existing validated bundles for the prevention of CDI,
the only recommendation graded “A-I” (to wear gloves when
handling feces) is already the standard of care, and the other
recommended CDI prevention practices can be difficult to
implement and monitor. In addition, because of the low qual-
ity of evidence to support most CDI prevention practices, the
costs of implementing and maintaining a recommendation
that may have minimal impact on CDI prevention must be
considered when designing a bundle of CDI-related preven-
tion practices.
A less formal bundle approach individualized to a health-
care facility can be a helpful tool as part of a CDI prevention
program; the bundle can be used to remind healthcare work-
ers of their role in CDI prevention. Abbett et al.11 created a
bundle in response to an increase in CDI incidence and se-
verity at their facility, which primarily reinforced adherence
to existing policies. After the education of healthcare staff on
their role in preventing CDI and the provision of visual re-
minders, the CDI incidence decreased from 1.10 to 0.66 cases
per 1,000 patient-days ( ). No data were collected onP ! .001
compliance with components of the bundle before or after
the intervention, so it is unclear which component of the
bundle may have had the greatest impact. However, there was
a significant increase in the number of stool specimens sent
to the laboratory for C. difficile testing after the intervention,
despite the decrease in the number of patients who received
a diagnosis of CDI, suggesting that more-rapid case finding
and initiation of CDI prevention practices that occur after a
patient receives a diagnosis of CDI contributed to a decrease
in CDI incidence.
how low is low enough?
As previously stated, most data on CDI prevention come from
outbreaks. When studied, many of the recommended prac-
tices to prevent CDI during outbreaks appear less effective
in settings of endemicity.12,13 The lack of knowledge on how
to further decrease CDI incidence in settings of endemicity
is stressed in the current draft of the “Action Plan to Prevent
Healthcare-Associated Infections” by the US Department of
Health and Human Services; it states that the “preventability
of endemic CDI is unknown.”14(p14) Therefore, we must con-
sider whether new approaches to CDI prevention are needed.
Two areas that need to be investigated further are whether
there are unrecognized sources of C. difficile transmission or
whether there are additional methods that can prevent CDI
before the onset of symptoms.
There may be unrecognized sources of C. difficile trans-
mission in the hospital and community. Several recent
publications have found C. difficile contamination of food.15
C. difficile can also contaminate hospital linens.16 Contami-
nated linens can then serve as a vector to contaminate other
linens during the laundering process.17 Although past studies
have found that the major source of C. difficile transmission
is from patients with symptomatic CDI, C. difficile can be
transmitted from asymptomatic carriers.18 Unfortunately,
there are no validated methods to detect asymptomatic C.
difficile carriers, and existing data indicate that currently avail-
able methods are not sufficiently sensitive or specific for the
rapid detection of asymptomatic C. difficile carriers.19 Un-
recognized sources of C. difficile transmission and methods
to prevent transmission from these sources need to be
investigated.
Most efforts to prevent CDI occur after a patient develops
symptomatic infection. Prevention of CDI in settings of en-
demicity may require emphasis on early prevention efforts—
that is, before the onset of CDI. One method being inves-
tigated is to identify patients at high risk for CDI through a
risk prediction model.20 Interventions could then be designed
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to decrease the risk in patients identified as high risk for CDI.
Another approach being investigated is the administration of
nontoxigenic C. difficile to protect against colonization by
toxigenic C. difficile, thus preventing CDI. In animal models,
administration of nontoxigenic C. difficile prior to challenge
with toxigenic C. difficile has been shown to be effective at
prevention of both an initial episode of CDI and recurrence
of CDI.21 A third area that holds promise is immunotherapy.
Patients asymptomatically colonized with C. difficile have
higher titers of antibodies against C. difficile, patients who
develop an anamnestic antibody after C. difficile acquisition
are at lower risk to develop CDI, and patients who fail to
produce antibodies against C. difficile after an episode of CDI
are at increased risk for developing recurrent episodes.22,23 A
recently published phase II trial evaluating anti–C. difficile
toxin monoclonal antibodies as adjunctive treatment for CDI
in addition to standard-of-care antibiotic treatment (with
metronidazole or vancomycin) demonstrated that patients
who received the monoclonal antibodies were significantly
less likely to have a recurrent episode of CDI, compared with
patients who received placebo (7% vs 25%; ).24 It isP ! .001
unlikely that a biological agent, such as monoclonal anti-
bodies, will be used as primary prophylaxis, because of the
typically high cost of such products. However, the results of
the trial suggest that CDI may at some point be added to the
list of vaccine-preventable diseases.25
conclusion
Currently, CDI prevention efforts are hampered by a lack of
high quality data to support most recommended prevention
practices, with only 2 practices that have good evidence to
support them (wearing gloves and antimicrobial steward-
ship). This makes the role of infection prevention and control
even more important when designing a CDI prevention pro-
gram or CDI bundles of CDI-related prevention practices, as
infection prevention and control must determine which pre-
vention practices to apply on the basis of local patient care
practices and CDI epidemiology. Currently, recommended
practices appear to be most effective when instituted in re-
sponse to a CDI outbreak, and the best methods to prevent
CDI in settings of endemicity are not known. More research
is needed to identify all sources of C. difficile transmission
and novel CDI prevention practices in order to significantly
decrease rates of CDI in hospitals across the United States.
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